EN
TradingView
Ticker Trading Ideas Educational Ideas Scripts People
Profile Profile Settings Account and Billing Referred friends Coins My Support Tickets Help Center Sign Out Upgrade Upgrade now 30-day Free Trial Start free trial Upgrade plan Pay nothing extra Upgrade early Get 6 months free Use last chance Get a month for $1
Markets US Stocks Health Technology Biotechnology

ATRECA INC
BCEL NASDAQ

BCEL
ATRECA INC NASDAQ
Trade now
 
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Trade now
Overview
Ideas Technicals Financials

BCEL Stock Chart

Ideas

Videos only
Hull Moving
BCEL
, 60
Long
BCEL: Hull Moving

Hull Moving Averages ( x3) all turned up going to run up for awhile with some dips. in at $13.08 x 400

ATRECA
BCEL
, 1D
Long
BCEL: ATRECA

price drop after public offering at $16 in future stock should test $24

BCEL - Make or break moment; 40% potential UP or DOWN
BCEL
, 1D
BCEL: BCEL - Make or break moment; 40% potential UP or DOWN

Atreca has come down to rising channel support. There's also the 100 ema involved, which has many times acted as watershed support\resistance (YELLOW arrows). If this channel and moving average hold, BCEL could quickly go back to all-time highs for a 44% gain. If channel breaks to the downside, March lows are 40% away. I would absolutely wait for solid...

BCEL review
BCEL
, 1D
BCEL: BCEL review

This is a review of my previous chart setup. Over 18%! I’m rich now lol. My best chart setup so far. Glad some of you guys could have made money on this one. If you want to hold this stock that’s completely ok but I am going to sell tomorrow.

BCEL
BCEL
, 1D
Long
BCEL: BCEL

Closed over support with super high volume! Is the bearish trend over?

Technicals

Financials

Valuation
Enterprise Value/EBITDA, TTM —
Enterprise Value, FQ —
Market Cap — Basic —
Number of Employees —
Number of Shareholders —
Price/Earnings, TTM —
Price/Revenue, TTM —
Price/Book Ratio, FY —
Price/Sales Ratio, FY —
Balance Sheet
Current Ratio, FQ —
Debt to Equity, FQ —
Net Debt, FQ —
Quick Ratio, FQ —
Total Assets, FQ —
Total Debt, FQ —
Operating Metrics
Return on Assets, TTM —
Return on Equity, TTM —
Return on Invested Capital, TTM —
Revenue per Employee, TTM —
Price History
Average Volume (10 day) —
Beta - 1 Year —
Price - 52 Week High —
Price - 52 Week Low —
Dividends
Dividends Paid, FY —
Dividends per Share, FY —
Expected Annual Dividends —
Dividends Yield —
Margins
Net Margin, TTM —
Gross Margin, TTM —
Operating Margin, TTM —
Pretax Margin, TTM —
Income Statement
Basic EPS, Net Income —
Earnings per Share, Basic, TTM —
EBITDA, TTM —
Gross Profit, FY —
Last Annual EPS —
Last Annual Revenue, FY —
Net Income, FY —
Total Revenue, FY —
Free Cash Flow, TTM —
More financials

Profile

Sector: Health Technology
Industry: Biotechnology
Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in South San Francisco, CA.

News

Home Stock Screener Forex Screener Crypto Screener Economic Calendar About Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Referred friends Coins My Support Tickets Help Center Private Messages Chat Sign Out
Upgrade Upgrade now 30-day Free Trial Start free trial Upgrade plan Pay nothing extra Upgrade early Get 6 months free Use last chance Get a month for $1